Samchundang Pharmaceutical said Tuesday that it has signed an agreement to supply six of its drugs to Glenmark Pharmaceuticals. The six drug products are four glaucoma treatments, an anti-allergy agent and anti-microbial agent.

The contract is a conditional agreement subject to the approval by the U.S. Food and Drug Administration (FDA).

If approval goes as planned, Samchundang will receive a 647.9 million won ($603,000) in down payment under a 10-year contract that starts on the date of the first shipment after approval. The company will also get 70 percent of gross profit from their sales.

Samchungdang expects to earn about 649.1 billion won in profits through the contract period.

“Through this export contract, the company has laid down a foundation for supplying ophthalmological reproduction products to the U.S. market in the future,” a company official said.

The two companies are also establishing a strategic partnership in the U.S. ophthalmic field, discussing to make more business accords.

Copyright © KBR Unauthorized reproduction, redistribution prohibited